title: Determination of bioavailability and systemically available fractions of drugs undergoing reversible metabolism: application to 4-amino-5-chloro-2-[2-(methylsulfinyl)ethoxy]-N-[2- (diethylamino)ethyl]benzamide and its sulfide and sulfone metabolites in rats.
abstract: Methods are discussed which permit the calculation of the bioavailability (F) and fraction of an oral dose entering the central circulation (f) of a drug and its interconversion metabolite. The interrelationships between the F and f and between the F and systemically available fractions afforded by reversible metabolism are also derived and described. The application of these principles is illustrated by the pharmacokinetic analysis of 4-amino-5-chloro-2-[2-(methylsulfinyl)ethoxy]-N-[2- (diethylamino)ethyl]benzamide (ML-1035, 1) and its sulfide (2) and sulfone (3) metabolites in rats. Like intravenous ML-1035, ML-1035 administered orally underwent metabolic interconversion with 2 but not with 3 in this species. Both ML-1035 and 2 were absorbed rapidly and are pharmacologically active. On average, 8.3 and 13% of an oral dose (152.4 mumol/kg) of ML-1035 were bioavailable as ML-1035 and its sulfide metabolite, respectively, while 23 and 65% of a molar equivalent dose of the sulfide metabolite were bioavailable as either compound, respectively. Thus, the sulfide metabolite is better absorbed than ML-1035 in rats. Following oral administration of either ML-1035 or 2, the systemically available fractions of both compounds were weakly to moderately influenced by the reversible metabolism process in rats. Moreover, the bioavailability of the sulfone metabolite was very poor (2.5-4%) following separate oral administration of ML-1035, 2, and 3.
authors.affiliation: Department of Drug Metabolism, Marion Merrell Dow Inc., Kansas City, MO 64134.
authors.forename: B S
authors.initials: BS
authors.lastname: Kuo
authors.forename: J C
authors.initials: JC
authors.lastname: Poole
authors.forename: K K
authors.initials: KK
authors.lastname: Hwang
authors.forename: H
authors.initials: H
authors.lastname: Cheng
mesh_terms: D000818:Animals; D001682:Biological Availability; D001711:Biotransformation; D006207:Half-Life; D008297:Male; D008787:Metoclopramide / Q000031:analogs & derivatives* / Q000097:blood / Q000493:pharmacokinetics; D051381:Rats; D017207:Rats, Sprague-Dawley; D012702:Serotonin Antagonists; D013440:Sulfides / Q000097:blood / Q000493:pharmacokinetics; D013450:Sulfones / Q000097:blood / Q000493:pharmacokinetics
chemical_list: D012702:Serotonin Antagonists; D013440:Sulfides; D013450:Sulfones; C071737:ML 1035; D008787:Metoclopramide